Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to study the feasibility and Toxicity of allogeneic haploidentical hematopoietic cell transplantation with CD3/CD19 depleted stem cells and a dose reduced conditioning.
Condition or disease
Drug: FludarabineDrug: ThiotepaDrug: MelphalanDrug: OKT-3Procedure: CD3/CD19 depletion on CliniMACS
Phase 1Phase 2
Transplantation of a CD3/CD19 depleted stem cell grafts after dose reduced conditioning for the treatment of treatment refractory or relapsed hematologic malignancies after preceding allogeneic or autologous hematopoietic cell transplantation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age <60, >18 years
High risk hematologic malignancy or relapse after preceding auto/allo HCT in patients with:
MDS (RAEB-t/secondary AML)
No HLA-identical MRD or URD if not preceding allo-HCT
Use haploidentical donor with KIR-Mismatch if choice
< 3 months after preceding HCT
Active cerebral seizures
> 30% blasts in BM if ALL/AML/CML-BC
Preceding myocardial infarction
Ejection fraction <30 % echocardiography
Creatinine clearance <50 ml/min
Respiratory insufficiency on supplemental O2 or DLCO < 30%